melanoma
|
|
0.780 |
GeneticVariation
|
BEFREE |
We observed an increase in NRAS mutant allele percentage (NRAS-MA%) in the metastatic melanoma progression from 2 patients with melanomas harbouring a NRAS mutation (p.Q61K in case 1 and p.Q61R in case 2).
|
26990546 |
2016 |
melanoma
|
|
0.780 |
GeneticVariation
|
BEFREE |
Here, using a bigenic mouse model system combining mutant oncogenic NRAS(Q61K) (constitutively active RAS) or mutant activated CDK4(R24C/R24C) (prevents binding of CDK4 by kinase inhibitor p16(INK4A)) with an epidermis-specific knockout of the nuclear retinoid X receptor alpha (RXRα(ep-/-)) results in increased melanoma formation after chronic ultraviolet-B (UVB) irradiation compared with control mice with functional RXRα.
|
25189354 |
2015 |
melanoma
|
|
0.780 |
GeneticVariation
|
BEFREE |
Nine cases presented concomitant BRAF and NRAS mutations, including one case in which both the melanoma and the adjacent naevus harboured V600E and Q61K double mutations.
|
25857817 |
2015 |
melanoma
|
|
0.780 |
GeneticVariation
|
BEFREE |
In this study, we performed an integrative analysis of DNA methylation, gene expression, and microRNA expression data to identify potential regulatory pathways associated with the most common driver mutations in NRAS (Q61K/L/R) through comparison of NRASQ61-mutated melanomas with pan-negative melanomas.
|
25537510 |
2015 |
melanoma
|
|
0.780 |
GeneticVariation
|
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
melanoma
|
|
0.780 |
CausalMutation
|
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
melanoma
|
|
0.780 |
CausalMutation
|
CLINVAR |
Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.
|
23614898 |
2013 |
melanoma
|
|
0.780 |
GeneticVariation
|
BEFREE |
Strikingly, the administration of BI-69A11 inhibited melanoma development in genetically modified mice bearing an inducible form of activated Nras and a deletion of the Ink4a gene (Nras((Q61K)) ::Ink4a(-/-) ).
|
23035722 |
2013 |
melanoma
|
|
0.780 |
CausalMutation
|
CLINVAR |
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.
|
23414587 |
2013 |
melanoma
|
|
0.780 |
CausalMutation
|
CLINVAR |
Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS-mutant melanoma.
|
23538902 |
2013 |
melanoma
|
|
0.780 |
CausalMutation
|
CLINVAR |
Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
|
23569304 |
2013 |
melanoma
|
|
0.780 |
GeneticVariation
|
CLINVAR |
We generated mutant BRAF(V600E) melanoma cells that exhibit resistance to PLX4720, the tool compound for vemurafenib, that co-expressed mutant (Q61K) NRAS.
|
23076151 |
2012 |
melanoma
|
|
0.780 |
CausalMutation
|
CLINVAR |
First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors.
|
22761467 |
2012 |
melanoma
|
|
0.780 |
GeneticVariation
|
BEFREE |
Molecular genetic analysis, including DNA sequencing and CGH, revealed that both areas contained an identical NRAS Q61K mutation and had highly similar CGH profiles, including gains of chromosome 1q and losses of 1p, 4, 9, and 10, which are archetypical of melanoma.
|
21836492 |
2011 |
melanoma
|
|
0.780 |
GeneticVariation
|
BEFREE |
We have evaluated five real-time ARMS assays: BRAF 1799T>A, [this includes V600E and V600K] and NRAS 182A>G [Q61R] and 181C>A [Q61K] in melanoma, EGFR 2573T>G [L858R], 2235-2249del15 [E746-A750del] in non-small-cell lung cancer, and compared the results to DNA sequencing of the mutation 'hot-spots' in these genes in formalin-fixed paraffin-embedded tumour (FF-PET) DNA.
|
20925915 |
2010 |
melanoma
|
|
0.780 |
CausalMutation
|
CLINVAR |
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.
|
20130576 |
2010 |
melanoma
|
|
0.780 |
CausalMutation
|
CLINVAR |
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.
|
20179705 |
2010 |
melanoma
|
|
0.780 |
GeneticVariation
|
BEFREE |
In summary, this report indicates that N-RAS(Q61K) and B-RAF(V600E) contribute to melanoma's resistance to apoptosis in part by downregulating Bim expression, suggesting that Bim is a possible treatment target for overriding melanoma's inherent defenses against cell death.
|
18668139 |
2009 |
melanoma
|
|
0.780 |
CausalMutation
|
CLINVAR |
Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.
|
18390968 |
2008 |
melanoma
|
|
0.780 |
CausalMutation
|
CLINVAR |
Distinct sets of genetic alterations in melanoma.
|
16291983 |
2005 |
melanoma
|
|
0.780 |
CausalMutation
|
CLINVAR |
Ras mutations in human melanoma: a marker of malignant progression.
|
8120410 |
1994 |
melanoma
|
|
0.780 |
CausalMutation
|
CLINVAR |
N-ras mutations in human cutaneous melanoma from sun-exposed body sites.
|
2674680 |
1989 |